Skip to main content

A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases

Objective

MAILPAN (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients. The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011. Next step is now to bring the prototype to the pre-clinical and clinical phases necessary to the ensuing commercialization of MAILPAN whose ultimate goal is to improve the life of at least 20 million persons in the world while providing positive effects on healthcare management and expenses, the environment and the competitiveness of the biomaterials industry.

In order to reach this goal, CeeD and Defymed gathered a consortium made of seven partners from academia, clinical/public health research sector and industry/SMEs from three different European countries –Belgium, France and UK. The expertise gathered include encapsulation techniques, islet isolation, cell engineering, islet transplantation, islet preconditioning, surgical implantation, and medium formulation; items that are complementary and necessary to the implementation of the present project proposal.

The project proposal of a 48-month duration intends to bring the most modern and up to date improvements that the bioartificial pancreas still needs and can receive such as to enhance cells survival inside the device by formulating a new adapted cell culture medium, to further lower the rejection risk by studying the biocompatibility and anti-inflammatory mechanisms, to test the prototype in small and large animal models, and to secure its further use in humans. Safety and bio-compatibility of MAILPAN device combined to the islets/pseudo-islets, will be assessed, in respect to the applied regulatory directives.

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

CENTRE EUROPEEN D'ETUDE DU DIABETE
Address
Boulevard Rene Leriche
67200 Strasbourg
France

See on map

Activity type
Other
Administrative Contact
Severine Sigrist (Dr.)
EU contribution
€ 812 317,60

Participants (7)

AvantiCell Science Ltd
United Kingdom
EU contribution
€ 484 927,20
Address
Gibbsyard Building
KA6 5HW Ayr

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Colin Wilde (Dr.)
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
France
EU contribution
€ 425 000
Address
Avenue Du Doyen Gaston Giraud 191
34000 Montpellier

See on map

Activity type
Research Organisations
Administrative Contact
Valérie Handweiler (Mrs.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 1 073 262
Address
Wellington Square University Offices
OX1 2JD Oxford

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Linda Pialek (Ms.)
DEFYMED
France
EU contribution
€ 636 050
Address
9 Rue Albert Calmette
67200 Strasbourg

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Richard Bou Aoun (Dr.)
HUMAN CELL DESIGN
France
EU contribution
€ 601 400
Address
Place Pierre Potier Centre Pierre Potier Canceropole Entree B 1
31000 Toulouse

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anne-Fabienne Weitsch (Dr.)
SARL ENDOCELLS

Participation ended

France
Address
Boulevard Saint Germain 216
75007 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anne-Fabienne Weitsch (Dr.)
UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgium
EU contribution
€ 1 136 546
Address
Place De L Universite 1
1348 Louvain La Neuve

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pierre Gianello (Prof.)